AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|AAPL327.36+0.77 (+0.23%) ▲|ABBV255.33+1.95 (+0.77%) ▲|ABT100.05-1.61 (-1.58%) ▼|ACN140.89-3.84 (-2.65%) ▼|ADBE226.71-8.03 (-3.42%) ▼|AMAT567.75+42.05 (+8.00%) ▲|AMD541.70+38.13 (+7.57%) ▲|AMGN364.49+0.32 (+0.09%) ▲|AMT163.75-3.32 (-1.98%) ▼|AMZN248.49-1.51 (-0.60%) ▼|AVGO386.17+8.01 (+2.12%) ▲|AXP351.03-0.90 (-0.26%) ▼|BA204.31-5.18 (-2.47%) ▼|BAC61.30+0.88 (+1.45%) ▲|BKNG177.97-1.48 (-0.82%) ▼|BLK1,040.96-13.15 (-1.25%) ▼|BMY60.47+0.31 (+0.51%) ▲|BNY158.67+1.74 (+1.11%) ▲|BRK-B489.69-1.56 (-0.32%) ▼|C132.90+4.18 (+3.25%) ▲|CAT889.71+25.41 (+2.94%) ▲|CL90.08-1.86 (-2.02%) ▼|CMCSA23.78-0.01 (-0.02%) ▼|COF206.12-0.65 (-0.31%) ▼|COP117.06+1.38 (+1.19%) ▲|COST931.02-4.78 (-0.51%) ▼|CRM170.24-3.55 (-2.04%) ▼|CSCO111.37+0.67 (+0.61%) ▲|CVS109.60+1.99 (+1.85%) ▲|CVX189.98+0.27 (+0.14%) ▲|DE589.47+3.47 (+0.59%) ▲|DHR178.69-22.42 (-11.15%) ▼|DIS96.50+0.09 (+0.09%) ▲|DUK125.59-0.26 (-0.21%) ▼|EMR139.43+2.85 (+2.09%) ▲|FDX314.80+8.58 (+2.80%) ▲|GD369.90-0.70 (-0.19%) ▼|GE340.98-0.33 (-0.10%) ▼|GEV1,083.23+4.05 (+0.38%) ▲|GILD129.80-3.41 (-2.56%) ▼|GM79.64+3.84 (+5.07%) ▲|GOOG348.19-3.18 (-0.91%) ▼|GOOGL348.89-3.10 (-0.88%) ▼|GS1,082.40+27.37 (+2.59%) ▲|HD330.63-2.41 (-0.72%) ▼|HON230.23+4.05 (+1.79%) ▲|IBM211.29-1.71 (-0.80%) ▼|INTC105.07+8.01 (+8.25%) ▲|INTU290.07-3.76 (-1.28%) ▼|ISRG357.26+4.09 (+1.16%) ▲|JNJ249.27+0.45 (+0.18%) ▲|JPM344.88+6.01 (+1.77%) ▲|KO82.09-0.04 (-0.04%) ▼|LIN506.73-5.32 (-1.04%) ▼|LLY1,163.31+16.41 (+1.43%) ▲|LMT505.40-4.14 (-0.81%) ▼|LOW203.42-1.29 (-0.63%) ▼|LRCX320.97+14.21 (+4.63%) ▲|MA538.78-8.66 (-1.58%) ▼|MCD265.19-2.45 (-0.92%) ▼|MDLZ59.79-0.49 (-0.80%) ▼|MDT82.31-0.98 (-1.18%) ▼|META647.02+1.17 (+0.18%) ▲|MMM169.90+10.79 (+6.78%) ▲|MO73.31-1.36 (-1.81%) ▼|MRK125.69+1.29 (+1.04%) ▲|MS215.36+4.42 (+2.10%) ▲|MSFT398.61-3.68 (-0.91%) ▼|MU974.66+109.20 (+12.62%) ▲|NEE87.92-0.08 (-0.09%) ▼|NFLX67.46-0.15 (-0.21%) ▼|NKE43.11-0.37 (-0.84%) ▼|NOW101.47-3.24 (-3.09%) ▼|NVDA206.09+2.81 (+1.38%) ▲|ORCL126.60+5.22 (+4.30%) ▲|PEP134.75-0.71 (-0.52%) ▼|PFE24.86+0.11 (+0.42%) ▲|PG147.65-1.49 (-1.00%) ▼|PLTR132.86-1.99 (-1.48%) ▼|PM189.68-3.04 (-1.58%) ▼|QCOM172.97+2.65 (+1.55%) ▲|RTX194.98+0.54 (+0.28%) ▲|SBUX104.48-0.33 (-0.31%) ▼|SCHW100.69-1.85 (-1.80%) ▼|SO93.68-0.78 (-0.83%) ▼|SPG226.54-1.65 (-0.72%) ▼|T22.09+0.14 (+0.62%) ▲|TMO523.98-2.25 (-0.43%) ▼|TMUS191.72-3.92 (-2.00%) ▼|TSLA380.14+10.57 (+2.86%) ▲|TXN293.49+9.42 (+3.32%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH434.26+12.71 (+3.02%) ▲|UNP294.41-1.85 (-0.62%) ▼|UPS115.91+2.76 (+2.43%) ▲|USB63.35+0.21 (+0.32%) ▲|V356.82-3.76 (-1.04%) ▼|VZ43.47-0.03 (-0.07%) ▼|WFC87.96+1.63 (+1.89%) ▲|WMT110.46-1.74 (-1.55%) ▼|XOM150.90+2.54 (+1.71%) ▲|
27.4 C
New York
Tuesday, July 21, 2026

Tag: exosome

newssourceFORcompanyinformationcontent1releasesmarket

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

Induction Therapies Introduces YouthXO + PDRN: A Next-Generation Recovery Serum for At Home Care

Powerful antioxidant protection meets post-treatment recovery for radiant, healthy-looking skinLOUISVILLE, Ky., June 15, 2026 /PRNewswire/ -- Induction Therapies, a leader in innovative skincare solutions...

CAREstream America introduces new era of science-backed innovation to deliver a new standard of quality to the US aesthetic market

CAREstream America announces an exclusive distribution partnership to bring Celltermi HS and NX Plus, an advanced probiotic-derived microbiome technology, to the US market. Celltermi...

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

MISOORA Unveils Revolutionary K-Beauty Skincare Range Emphasizing Longevity Over Anti-Aging

A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut. 
A five-step biotech regimen, anchored by NAD+ and Retinaldehyde, opens its founding waitlist ahead of a June 22 US debut.

Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited

Transaction Expected to Close in the Coming Days

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET – 
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update

Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading...

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November 
Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November

CAPR Class Action Alert: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Capricor Therapeutics, Inc. Securities Class Action

Robbins LLP is Investigating Allegations that Capricorn Therapeutics, Inc. (CAPR) Misled Investors Regarding the Viability of Deramiocel

Exosome Research Global Market Forecasts 2025-2030 | Key Market Players Paving the Way for Advancements in Exosome-Based Diagnostics and Therapeutics

The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled. 
The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled.

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner 
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

From Stem Cells to CAR-T: LivMedCell Expands Its Role in the Future of Medicine

LivMedCell is Turkey’s first hospital-based stem cell production center operating under GMP standards, located within Liv Hospital in Istanbul.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsExosome

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers